-
BTIG: Buy Teva On Weakness, U.S. Lawmakers Have Little Appetite For Direct Government Negotiation Of Drug Prices
Monday, March 21, 2016 - 8:56am | 272Read More...BTIG's Timothy Chiang maintained a Buy rating on Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), with a $77 price target. Buy The Weakness Although the stock has declined 17 percent year-to-date, it has outperformed specialty pharma sector as a whole, which is down 34 percent....
-
BTIG Recommends 'Beaten Down' Drug Manufacturers Like Teva
Monday, March 7, 2016 - 11:31am | 336Read More...BTIG’s Timothy Chiang mentioned that shares of specialty pharmaceutical companies are down 20 percent year-to-date, as compared to a 5.8 percent decline in the S&P 500. The decline is largely attributable to investor concerns surrounding the sustainability of earnings growth and the...
